Sarepta Therapeutics, Inc. (SRPT) Stock Price & Analysis

Sarepta Therapeutics, Inc. (SRPT) rose 2.19% to USD 15.89 as of June 10, 2026 at 00:50 UTC, according to Nexqual real-time market data.

SRPT last closed at USD 15.55; the session ranged USD 15.42–16.28 on volume of 1,863,164 shares. Market capitalization is $1.68B, with a 52-week range of USD 10.42–40.9 (NMS). Source: Nexqual, June 10, 2026 at 00:50 UTC.

Key Statistics (as of June 10, 2026 at 00:50 UTC)

Technical Analysis (SRPT)

Nexqual's technical model rates SRPT "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:50 UTC.

Analyst Ratings (SRPT)

Wall Street analysts rate SRPT "Hold" based on 23 analysts, with a mean price target of USD 22 (range USD 5–38), per Nexqual as of June 10, 2026 at 00:50 UTC.

Earnings (SRPT)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 00:50 UTC.

Financials & Fundamentals (SRPT)

Source: Nexqual, June 10, 2026 at 00:50 UTC.

Financial Health Score (SRPT)

Nexqual rates Sarepta Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:50 UTC.

Ownership (SRPT)

Source: Nexqual, June 10, 2026 at 00:50 UTC.

Leadership (SRPT)

Sarepta Therapeutics, Inc. is led by Douglas S. Ingram Esq. (age 62), CEO & Director, per Nexqual as of June 10, 2026 at 00:50 UTC.

Major Backers & Investors (SRPT)

Notable institutional backers of Sarepta Therapeutics, Inc. include AQR Capital Management, LLC, Two Sigma Investments, LP, First Trust Advisors LP, according to Nexqual as of June 10, 2026 at 00:50 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 00:50 UTC.

From Sarepta Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)

Key Strengths & Strategy (as disclosed to the SEC)

• Applying our proprietary, differentiated and innovative technologies, and through collaborations with our strategic partners, we have developed multiple approved products for the treatment of Duchenne muscular dystrophy ("Duchenne") and are developing potential therapeutic candidates for a broad range of diseases and disorders, including Duchenne and LGMD.
• The chart below summarizes the status of our programs, including those with our strategic partners:   Manufacturing, Supply and Distribution We have developed proprietary state-of-the-art Chemistry, Manufacturing and Controls ("CMC") capabilities that allow manufacturing and testing of our products and product candidates to support both clinical development and commercialization.
• Objectives and Business Strategy We believe that our proprietary technology platforms and collaborations can be used to develop novel pharmaceutical products to treat a broad range of diseases and address key currently-unmet medical needs.
• The original PMO structure and variations of this structure that are so-called PMO-based (collectively "PMO-based") are central to our proprietary chemistry platform.

Partnerships

• University of Western Australia In April 2013, we entered into an agreement with UWA under which an existing exclusive license agreement between the two parties was amended and restated and, in June 2016, we entered into the first amendment to the license agreement (the "UWA License Agreement").
• Consequently, the Company entered into an agreement with Arrowhead to transfer approximately 2.7 million shares of Arrowhead common stock, valued at approximately $50.0 million.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:50 UTC. This page is informational and not investment advice.